JP2017537626A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537626A5
JP2017537626A5 JP2017529610A JP2017529610A JP2017537626A5 JP 2017537626 A5 JP2017537626 A5 JP 2017537626A5 JP 2017529610 A JP2017529610 A JP 2017529610A JP 2017529610 A JP2017529610 A JP 2017529610A JP 2017537626 A5 JP2017537626 A5 JP 2017537626A5
Authority
JP
Japan
Prior art keywords
guide rna
synthetic guide
linkage
rna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529610A
Other languages
English (en)
Other versions
JP2017537626A (ja
JP7068821B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/000143 external-priority patent/WO2016089433A1/en
Publication of JP2017537626A publication Critical patent/JP2017537626A/ja
Publication of JP2017537626A5 publication Critical patent/JP2017537626A5/ja
Priority to JP2022020615A priority Critical patent/JP2022078083A/ja
Application granted granted Critical
Publication of JP7068821B2 publication Critical patent/JP7068821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. (c)(i)ポリヌクレオチド中の標的配列とハイブリダイズ可能なガイド配列、(ii)ステム配列を含むcrRNAセグメントと、
    (d)ステム配列と部分的または完全に相補的であるヌクレオチド配列を含むtracrRNAセグメントと
    を含む合成ガイドRNAであって、
    1つまたは複数の修飾を含み、gRNA機能性を有する合成ガイドRNA。
  2. 前記修飾のうち1つまたは複数が、安定性増強性修飾を含む、請求項1に記載の合成ガイドRNA。
  3. 前記安定性増強性修飾が、2’−O−メチル部分、Z塩基、2’−デオキシヌクレオチド、ホスホロチオエートヌクレオチド間連結、ホスホノ酢酸(PACE)ヌクレオチド間連結またはチオホスホノ酢酸(チオPACE)ヌクレオチド間連結またはそれらの組合せを含む、請求項2に記載の合成ガイドRNA。
  4. 3’−ホスホロチオエート基を有する2’−O−メチルヌクレオチド、3’−ホスホノ酢酸基を有する2’−O−メチルヌクレオチド、3’−チオホスホノ酢酸基を有する2’−O−メチルヌクレオチドおよび3’−ホスホノ酢酸基を有する2’−デオキシヌクレオチドからなる群から選択される1つまたは複数の修飾を含む、請求項1〜3のいずれか1項に記載の合成ガイドRNA。
  5. 単一RNA鎖または2つの別個のRNA鎖ならびに各RNA鎖の5’末端に、各RNA鎖の3’末端に、または各RNA鎖の5’末端および3’末端の両方に1つまたは複数の修飾を含む、請求項1〜4のいずれか1項に記載の合成ガイドRNA。
  6. 5’末端に、または3’末端に、または5’および3’末端の各々に、7以下の連続する修飾されたヌクレオチドを含む、請求項に記載の合成ガイドRNA。
  7. 前記修飾のうち1つまたは複数が、塩基対形成熱安定性を変更する、請求項1〜6のいずれか1項に記載の合成ガイドRNAであって、前記1つまたは複数の修飾が、2−チオウラシル(2−チオU)、4−チオウラシル(4−チオU)、2−アミノアデニン、2’−O−メチル、2’−フルオロ、5−メチルウリジン、5−メチルシチジン、ロックド核酸修飾(LNA)、2’−デオキシ、ホスホロチオエート連結、ジチオリン酸連結、ボラノホスホネート連結、ホスホノ酢酸連結、チオホスホノ酢酸連結およびアンロックド核酸修飾(ULNA)から独立に選択される、合成ガイドRNA。
  8. 前記修飾のうちの1つまたは複数が、特異性変更性修飾である、請求項1〜7のいずれか1項に記載の合成ガイドRNA。
  9. 前記特異性変更性修飾が、ガイド配列中に位置する、請求項に記載の合成ガイドRNA。
  10. 前記特異性変更性修飾が、2−チオウラシル、4−チオウラシル、2−アミノアデニン、2’−O−メチル、2’−フルオロ、LNA、ホスホロチオエート連結、ジチオリン酸連結、ボラノホスホネート連結、ホスホノ酢酸連結、チオホスホノ酢酸連結、ULNA、2’−デオキシ、5−メチルウリジン、5−メチルシチジンまたはそれらの組合せを含む、請求項に記載の合成ガイドRNA。
  11. 蛍光色素または標識を含む、請求項1〜10のいずれか1項に記載の合成ガイドRNA。
  12. 前記蛍光色素または標識が、合成ガイドRNAのステム−ループと結合している、請求項11に記載の合成ガイドRNA。
  13. DNA配列を修飾するためにゲノム編集する、または対象の遺伝子の発現を調節する、または標的ポリヌクレオチドを切断するための方法であって、DNA配列、対象の遺伝子または標的ポリヌクレオチドを、CRISPR関連タンパク質および前述の請求項のいずれか1項に記載の合成ガイドRNAと接触させること、ならびにDNA配列、対象の遺伝子または標的ポリヌクレオチドを編集、調節または切断することを含む、方法。
  14. in vitroで実施され、合成ガイドRNAが、ガイド配列中全体に15以上の2’−O−メチル修飾を含む、請求項13に記載の方法。
  15. 請求項1〜14のいずれか1項に記載の合成ガイドRNAを2種以上含むRNA分子のセットまたはライブラリー。
JP2017529610A 2014-12-03 2015-12-03 化学修飾を有するガイドrna Active JP7068821B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022020615A JP2022078083A (ja) 2014-12-03 2022-02-14 化学修飾を有するガイドrna

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462087211P 2014-12-03 2014-12-03
US62/087,211 2014-12-03
US201562146189P 2015-04-10 2015-04-10
US62/146,189 2015-04-10
US201562256095P 2015-11-16 2015-11-16
US62/256,095 2015-11-16
PCT/US2015/000143 WO2016089433A1 (en) 2014-12-03 2015-12-03 Guide rna with chemical modifications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022020615A Division JP2022078083A (ja) 2014-12-03 2022-02-14 化学修飾を有するガイドrna

Publications (3)

Publication Number Publication Date
JP2017537626A JP2017537626A (ja) 2017-12-21
JP2017537626A5 true JP2017537626A5 (ja) 2019-01-17
JP7068821B2 JP7068821B2 (ja) 2022-05-17

Family

ID=56092183

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529610A Active JP7068821B2 (ja) 2014-12-03 2015-12-03 化学修飾を有するガイドrna
JP2022020615A Pending JP2022078083A (ja) 2014-12-03 2022-02-14 化学修飾を有するガイドrna

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022020615A Pending JP2022078083A (ja) 2014-12-03 2022-02-14 化学修飾を有するガイドrna

Country Status (8)

Country Link
US (4) US10900034B2 (ja)
EP (1) EP3227447B1 (ja)
JP (2) JP7068821B2 (ja)
KR (2) KR102629128B1 (ja)
CN (1) CN107250148B (ja)
AU (1) AU2015355546B2 (ja)
CA (1) CA2969619A1 (ja)
WO (1) WO2016089433A1 (ja)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CN111705365A (zh) 2014-02-11 2020-09-25 科罗拉多州立大学董事会(法人团体) Crispr支持的多路基因组工程化
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
AU2015355546B2 (en) 2014-12-03 2021-10-14 Agilent Technologies, Inc. Guide RNA with chemical modifications
WO2016097212A1 (en) 2014-12-17 2016-06-23 Proqr Therapeutics Ii B.V. Targeted rna editing
EP3234133B1 (en) 2014-12-18 2020-11-11 Integrated DNA Technologies, Inc. Crispr-based compositions and methods of use
US10738305B2 (en) 2015-02-23 2020-08-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
KR102648489B1 (ko) 2015-04-06 2024-03-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
WO2017004261A1 (en) 2015-06-29 2017-01-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
WO2017004279A2 (en) 2015-06-29 2017-01-05 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
CN108472314A (zh) 2015-07-31 2018-08-31 明尼苏达大学董事会 修饰的细胞和治疗方法
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
JP7067793B2 (ja) 2015-10-23 2022-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基編集因子およびその使用
EP3159407A1 (en) * 2015-10-23 2017-04-26 Silence Therapeutics (London) Ltd Guide rnas, methods and uses
US11845933B2 (en) 2016-02-03 2023-12-19 Massachusetts Institute Of Technology Structure-guided chemical modification of guide RNA and its applications
US10767175B2 (en) * 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
JP7074345B2 (ja) 2016-06-22 2022-05-24 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 一本鎖rna編集オリゴヌクレオチド
US10017760B2 (en) 2016-06-24 2018-07-10 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
EP3500671A4 (en) * 2016-08-17 2020-07-29 The Broad Institute, Inc. NEW CRISPR ENZYMS AND SYSTEMS
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102501980B1 (ko) 2016-09-01 2023-02-20 프로큐알 테라퓨틱스 Ⅱ 비.브이. 화학적으로 변형된 단일 가닥 rna-편집 올리고뉴클레오타이드
WO2018055577A1 (en) * 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
US11306305B2 (en) 2016-09-23 2022-04-19 Board Of Trustees Of Southern Illinois University Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
CA3037663A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified-rna oligonucleotide compositions and uses thereof
US10669539B2 (en) * 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
EP3523427A4 (en) 2016-10-07 2020-09-02 Integrated DNA Technologies, Inc. S. PYOGENES AND POLYPEPTIDES MUTANT CAS9 GENES CODED BY SUCH GENES
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
WO2018085414A1 (en) * 2016-11-02 2018-05-11 President And Fellows Of Harvard College Engineered guide rna sequences for in situ detection and sequencing
EP3541945A4 (en) * 2016-11-18 2020-12-09 Genedit Inc. COMPOSITIONS AND METHODS OF MODIFICATION OF TARGET NUCLEIC ACIDS
EP4321617A3 (en) 2016-11-22 2024-04-24 Integrated DNA Technologies Inc. Crispr/cpf1 systems and methods
AU2017374044B2 (en) 2016-12-08 2023-11-30 Intellia Therapeutics, Inc. Modified guide RNAs
US11293022B2 (en) 2016-12-12 2022-04-05 Integrated Dna Technologies, Inc. Genome editing enhancement
WO2018118587A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Modified polynucleotides for antiviral therapy
EA201991455A1 (ru) 2016-12-22 2020-01-15 Интеллиа Терапьютикс, Инк. Композиции и способы лечения дефицита альфа-1-антитрипсина
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
AU2017388379A1 (en) * 2016-12-28 2019-06-06 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and uses thereof
WO2018134301A1 (en) 2017-01-19 2018-07-26 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in rna editing
AU2018229351B2 (en) 2017-02-28 2024-01-04 Vor Biopharma, Inc. Compositions and methods for inhibition of lineage specific proteins
US20180258485A1 (en) * 2017-03-07 2018-09-13 The Regents Of The University Of Colorado, A Body Corporate Boranephosphonate Detection Probes and Methods For Producing and Using the Same
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
EP3601568A1 (en) 2017-03-31 2020-02-05 Agenovir Corporation Antiviral therapeutic
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3621981A2 (en) 2017-05-12 2020-03-18 CRISPR Therapeutics AG Materials and methods for engineering cells and uses thereof in immuno-oncology
CN108977442B (zh) * 2017-06-05 2023-01-06 广州市锐博生物科技有限公司 用于dna编辑的系统及其应用
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019051430A1 (en) * 2017-09-11 2019-03-14 Synthego Corporation METHOD AND SYSTEM FOR BIOPOLYMER SYNTHESIS
US20200270604A1 (en) 2017-09-19 2020-08-27 Tropic Biosciences UK Limited Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
WO2019084664A1 (en) * 2017-11-02 2019-05-09 The Governors Of The University Of Alberta Chemically-modified guide rnas to improve crispr-cas protein specificity
US11268092B2 (en) 2018-01-12 2022-03-08 GenEdit, Inc. Structure-engineered guide RNA
WO2019147743A1 (en) * 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
WO2019150196A1 (en) 2018-02-05 2019-08-08 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2019150203A1 (en) 2018-02-05 2019-08-08 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US11976092B2 (en) 2018-02-09 2024-05-07 Ohio State Innovation Foundation RNA nanostructures, methods of making, and uses thereof
KR20200132924A (ko) * 2018-03-14 2020-11-25 에디타스 메디신, 인코포레이티드 혈색소병증 치료를 위한 시스템 및 방법
EP3752632A4 (en) * 2018-03-19 2022-07-13 University of Massachusetts MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
EP3768328A4 (en) * 2018-03-23 2021-12-22 Refuge Biotechnologies, Inc. GENE REGULATION THROUGH CONDITIONAL NUCLEAR LOCALIZATION OF GENE-MODULATING POLYPEPTIDES
CA3101949A1 (en) * 2018-05-11 2019-11-14 Universite Laval Crispr/cas9 system and uses thereof
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
WO2019222545A1 (en) 2018-05-16 2019-11-21 Synthego Corporation Methods and systems for guide rna design and use
US11833225B2 (en) * 2018-05-24 2023-12-05 Crispr Therapeutics Ag Methods and compositions for efficient gene deletion
WO2019237069A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
WO2020005846A1 (en) * 2018-06-25 2020-01-02 Bionano Genomics, Inc. Labeling of dna
WO2020006423A1 (en) * 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US20210310002A1 (en) * 2018-08-31 2021-10-07 City Of Hope Cationic compounds for delivery of nucleic acids
GB201901873D0 (en) * 2019-02-11 2019-04-03 Proqr Therapeutics Ii Bv Antisense oligonucleotides for nucleic acid editing
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
EP3942040A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EA202192975A1 (ru) 2019-04-30 2022-02-01 Криспр Терапьютикс Аг Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
EP3973057A1 (en) 2019-05-23 2022-03-30 Vor Biopharma, Inc. Compositions and methods for cd33 modification
JP2021016370A (ja) * 2019-07-23 2021-02-15 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
JP2022545956A (ja) 2019-08-28 2022-11-01 ブイオーアール バイオファーマ インコーポレーテッド Cll1改変ための組成物および方法
MX2022002461A (es) 2019-08-28 2022-06-02 Vor Biopharma Inc Composiciones y métodos para la modificación de cd123.
AU2020358863A1 (en) 2019-10-03 2022-05-12 Artisan Development Labs, Inc. CRISPR systems with engineered dual guide nucleic acids
CN114502566A (zh) 2019-10-11 2022-05-13 住友化学株式会社 核酸寡聚物的制造方法
US20220348929A1 (en) * 2019-12-09 2022-11-03 Caribou Biosciences, Inc. Crispr abasic restricted nucleotides and crispr accuracy via analogs
IL293569A (en) * 2019-12-11 2022-08-01 Intellia Therapeutics Inc A modified rnas guide to gene editing
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
CN115003682A (zh) 2020-01-29 2022-09-02 住友化学株式会社 核酸寡聚物的制造方法
KR20220133919A (ko) 2020-01-29 2022-10-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
KR20220160010A (ko) 2020-03-27 2022-12-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022047168A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cll1 modification
WO2022047165A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cd123 modification
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
EP4211244A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Compositions and methods for cd38 modification
EP4214318A1 (en) 2020-09-18 2023-07-26 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022061247A2 (en) 2020-09-18 2022-03-24 Artisan Development Labs, Inc. Constructs and uses thereof for efficient and specific genome editing
CN116209668A (zh) 2020-09-24 2023-06-02 住友化学株式会社 核酸寡聚物的制造方法
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
US20230364146A1 (en) 2020-09-30 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
US20240000846A1 (en) 2020-10-27 2024-01-04 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
US20230414755A1 (en) 2020-11-13 2023-12-28 Vor Biopharma Inc. Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
CN112266951B (zh) * 2020-11-23 2021-07-20 广东省农业科学院植物保护研究所 一种生物素标记引物延伸方法及其应用
WO2022115878A1 (en) * 2020-11-30 2022-06-02 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas-mediated gene editing of human stem cells
WO2022147347A1 (en) 2020-12-31 2022-07-07 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
WO2022217086A1 (en) 2021-04-09 2022-10-13 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
CN113512767B (zh) * 2021-04-30 2022-09-23 天津诺禾致源生物信息科技有限公司 用于构建small RNA文库的接头、试剂盒及small RNA文库的构建方法
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022266538A2 (en) 2021-06-18 2022-12-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
WO2023283495A1 (en) * 2021-07-09 2023-01-12 The Brigham And Women's Hospital, Inc. Crispr-based protein barcoding and surface assembly
WO2023015182A1 (en) 2021-08-02 2023-02-09 Vor Biopharma Inc. Compositions and methods for gene modification
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023039586A1 (en) * 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
KR20240055098A (ko) * 2021-09-14 2024-04-26 애질런트 테크놀로지스, 인크. 화학적 변형을 갖는 가이드 rna를 사용하는 방법
WO2023049926A2 (en) 2021-09-27 2023-03-30 Vor Biopharma Inc. Fusion polypeptides for genetic editing and methods of use thereof
WO2023054350A1 (ja) 2021-09-28 2023-04-06 住友化学株式会社 精製ジクロロ酢酸の製造方法
TW202334419A (zh) * 2021-11-03 2023-09-01 美商英特利亞醫療公司 用於基因編輯之經修飾引導rna
WO2023086422A1 (en) 2021-11-09 2023-05-19 Vor Biopharma Inc. Compositions and methods for erm2 modification
WO2023164636A1 (en) 2022-02-25 2023-08-31 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
WO2023185697A2 (en) 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
WO2023196816A1 (en) 2022-04-04 2023-10-12 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
WO2023225410A2 (en) 2022-05-20 2023-11-23 Artisan Development Labs, Inc. Systems and methods for assessing risk of genome editing events
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024061296A2 (en) 2022-09-22 2024-03-28 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US7371580B2 (en) 2001-08-24 2008-05-13 Agilent Technologies, Inc. Use of unstructured nucleic acids in assaying nucleic acid molecules
WO2005065419A2 (en) 2003-12-29 2005-07-21 Am Biosolutions Method of culturing cells
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
KR101625363B1 (ko) 2007-05-10 2016-05-30 애질런트 테크놀로지스, 인크. Rna 합성을 위한 티오카본-보호기
US20100076183A1 (en) 2008-09-22 2010-03-25 Dellinger Douglas J Protected monomer and method of final deprotection for rna synthesis
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
SG10201606959PA (en) 2012-02-24 2016-09-29 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP2852602B1 (en) 2012-05-21 2020-08-12 Agilent Technologies, Inc. Method for conjugating oligonucleotides
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
TWI670004B (zh) 2012-09-07 2019-09-01 美商陶氏農業科學公司 用來產生植物之螢光激活細胞分選富增技術
RU2665811C2 (ru) 2012-09-07 2018-09-04 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Локусы fad3 для выполнения операций и соответствующие связывающиеся со специфическими сайтами-мишенями белки, способные к вызову направленных разрывов
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
CN116064532A (zh) 2012-10-23 2023-05-05 基因工具股份有限公司 用于切割靶dna的组合物及其用途
US20150315576A1 (en) 2012-11-01 2015-11-05 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
ES2682279T3 (es) 2012-12-06 2018-09-19 Synthetic Genomics, Inc. Mutantes de algas que tienen un fenotipo aclimatado a la luz intensa en compartimentos
WO2014089513A1 (en) 2012-12-06 2014-06-12 Synthetic Genomics, Inc. Autonomous replication sequences and episomal dna molecules
KR102243092B1 (ko) 2012-12-06 2021-04-22 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK3327127T3 (da) 2012-12-12 2021-06-28 Broad Inst Inc Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til sekvensmanipulation og terapeutiske anvendelser
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
ES2576128T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones para la manipulación de secuencias con dominios funcionales
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP4286404A3 (en) 2012-12-12 2024-02-14 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
IL307735A (en) * 2012-12-12 2023-12-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
IL308158A (en) 2012-12-17 2023-12-01 Harvard College RNA-guided human genome engineering
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
WO2014159719A1 (en) 2013-03-14 2014-10-02 Scrips Health Methods of isolating nucleic acids
CN105980575A (zh) 2013-03-14 2016-09-28 卡里布生物科学公司 以核酸为靶的核酸的组合物和方法
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
JP6980380B2 (ja) 2013-03-15 2021-12-15 ザ ジェネラル ホスピタル コーポレイション 短縮ガイドRNA(tru−gRNA)を用いたRNA誘導型ゲノム編集の特異性の増大
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
EP2971006A4 (en) 2013-03-15 2017-02-08 Transposagen Biopharmaceuticals, Inc. Reproducible method for testis-mediated genetic modification (tgm) and sperm-mediated genetic modification (sgm)
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
AU2014227831B2 (en) 2013-03-15 2020-01-30 Regents Of The University Of Minnesota Engineering plant genomes using CRISPR/Cas systems
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US11274305B2 (en) 2013-04-04 2022-03-15 Trustees Of Dartmouth College Compositions and methods for in vivo excision of HIV-1 proviral DNA
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
EP2986709A4 (en) 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
PL3456831T3 (pl) 2013-04-16 2021-12-06 Regeneron Pharmaceuticals, Inc. Ukierunkowana modyfikacja genomu szczura
US20160186208A1 (en) 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
AU2014273085B2 (en) 2013-05-29 2020-10-22 Cellectis New compact scaffold of Cas9 in the type II CRISPR system
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
JP7065564B2 (ja) 2013-05-29 2022-05-12 セレクティス Cas9ニッカーゼ活性を用いて正確なdna切断をもたらすための方法
MX2015016798A (es) 2013-06-04 2016-10-26 Harvard College Regulacion transcripcional guiada por acido ribonucleico.
EP3008181B1 (en) 2013-06-11 2019-11-06 The Regents of The University of California Methods and compositions for target dna modification
US20150315252A1 (en) 2013-06-11 2015-11-05 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
CA2915834A1 (en) 2013-06-17 2014-12-24 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
BR112015031611A2 (pt) 2013-06-17 2017-12-12 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para direcionamento e modelação de doenças e distúrbios de células pós-mitóticas
EP4245853A3 (en) 2013-06-17 2023-10-18 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
DK3011031T3 (da) 2013-06-17 2020-12-21 Broad Inst Inc Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
WO2014204723A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ CRISPR/Cas系を用いるゲノム編集の治療用の使用
KR20230122182A (ko) 2013-07-09 2023-08-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 멀티플렉스 rna-가이드된 게놈 조작
WO2015006437A1 (en) 2013-07-10 2015-01-15 Majzoub Joseph A Mrap2 knockouts
EP3666892A1 (en) 2013-07-10 2020-06-17 President and Fellows of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
ES2729635T3 (es) 2013-08-22 2019-11-05 Pioneer Hi Bred Int Modificación genómica usando sistemas de polinucleótido guía/endonucleasa Cas y métodos de uso
EP3041931B1 (en) 2013-09-04 2020-06-10 Csir Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
BR102014021800B1 (pt) 2013-09-04 2022-03-29 Dow Agrosciences Llc Método para detectar a integração específica de sítio de uma sequência de doador de polinucleotídeo dentro de um sítio-alvo genômico
WO2015035034A1 (en) 2013-09-04 2015-03-12 Mice With Horns, Llc Materials and methods for correcting recessive mutations in animals
US20150071946A1 (en) 2013-09-06 2015-03-12 The Johns Hopkins University Tumor-specific retrotransposon insertions
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
DE202014010413U1 (de) 2013-09-18 2015-12-08 Kymab Limited Zellen und Organismen
WO2015040075A1 (en) 2013-09-18 2015-03-26 Genome Research Limited Genomic screening methods using rna-guided endonucleases
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
AU2014331939A1 (en) 2013-10-08 2016-04-28 Amelia HENRY Drought-resistant cereal grasses and related materials and methods
DE102013111099B4 (de) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
AU2014341928B2 (en) 2013-11-04 2017-11-30 Corteva Agriscience Llc A universal donor system for gene targeting
WO2015066634A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal soybean loci
CN106232821A (zh) 2013-11-04 2016-12-14 美国陶氏益农公司 最优大豆座位
UY35812A (es) 2013-11-04 2015-05-29 Dow Agrosciences Llc ?loci de maíz óptimos?.
CA2928855A1 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal maize loci
WO2015070062A1 (en) 2013-11-07 2015-05-14 Massachusetts Institute Of Technology Cell-based genomic recorded accumulative memory
PT3066201T (pt) 2013-11-07 2018-06-04 Massachusetts Inst Technology Métodos e composições relacionadas com crispr com arng reguladores
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
WO2015075056A1 (en) 2013-11-19 2015-05-28 Thermo Fisher Scientific Baltics Uab Programmable enzymes for isolation of specific dna fragments
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
AU2014361781B2 (en) 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
EP3080260B1 (en) 2013-12-12 2019-03-06 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015089351A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
KR20160089530A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Hbv 및 바이러스 질병 및 질환을 위한 crispr­cas 시스템 및 조성물의 전달,용도 및 치료적 적용
US20150344836A1 (en) 2014-05-30 2015-12-03 Ohio State Innovation Foundation Agrobacterium Strains for Plant Transformation and Related Materials and Methods
CN106574256A (zh) 2014-05-30 2017-04-19 斯坦福大学托管董事会 用于潜伏病毒感染的递送治疗的组合物和方法
HUE049405T2 (hu) 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
IL286474B2 (en) 2014-06-23 2023-11-01 Massachusetts Gen Hospital Genome-wide random identification of DSBS assessed by sequencing (guide-sequence)
EP3164148A4 (en) 2014-06-25 2017-12-13 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
EP3778891A1 (en) 2014-08-27 2021-02-17 New England Biolabs, Inc. Synthon formation
NZ728437A (en) 2014-08-27 2018-02-23 Caribou Biosciences Inc Methods for increasing cas9-mediated engineering efficiency
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
AU2015321591B2 (en) 2014-09-26 2022-03-10 Pioneer Hi-Bred International, Inc. Wheat MS1 polynucleotides, polypeptides, and mehtods of use
JP6702951B2 (ja) 2014-09-26 2020-06-03 オンテラ インコーポレイテッド 合成プローブのナノ細孔センシングによる標的配列検出
US11666082B2 (en) 2014-09-26 2023-06-06 Philip Morris Products S.A. Reducing tobacco specific nitrosamines through alteration of the nitrate assimilation pathway
WO2016073079A2 (en) 2014-09-26 2016-05-12 Yale University Compositions and methods for biocontainment of microorganisms
EP3204050A4 (en) 2014-10-09 2018-04-04 The Regents of The University of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
AU2015330855A1 (en) 2014-10-09 2017-04-27 Celularity Inc. Placenta-derived adherent cell exosomes and uses thereof
US9879283B2 (en) 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
CA2964948A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
EP3212789B1 (en) 2014-10-31 2020-04-22 Massachusetts Institute of Technology Massively parallel combinatorial genetics for crispr
AU2015355546B2 (en) 2014-12-03 2021-10-14 Agilent Technologies, Inc. Guide RNA with chemical modifications
KR102648489B1 (ko) * 2015-04-06 2024-03-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
US20190075770A1 (en) 2015-12-18 2019-03-14 Japan Science And Technology Agency Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017106569A1 (en) 2015-12-18 2017-06-22 The Regents Of The University Of California Modified site-directed modifying polypeptides and methods of use thereof
KR20180086430A (ko) 2015-12-18 2018-07-31 다니스코 유에스 인크. 중합효소 ii(pol-ii) 기반의 가이드 rna 발현을 위한 방법 및 조성물
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
EP3390631B1 (en) 2015-12-18 2020-04-08 Danisco US Inc. Methods and compositions for t-rna based guide rna expression

Similar Documents

Publication Publication Date Title
JP2017537626A5 (ja)
ES2494940T3 (es) Moduladores de factores de coagulación mejorados
Steinkraus et al. Tiny giants of gene regulation: experimental strategies for microRNA functional studies
HRP20231022T1 (hr) Hibridni polinukleotidi crispr dna/rna i načini uporabe
JP2015142558A5 (ja)
JP2018512041A5 (ja)
WO2017181107A2 (en) Modified cpf1 mrna, modified guide rna, and uses thereof
JP2018512110A5 (ja)
RU2017117510A (ru) Редактирование целевой рнк
JP2014527401A5 (ja)
JP2019508051A5 (ja)
IL258230B (en) Oligonucleotide preparations and methods thereof
TW202043249A (zh) 編輯rna的方法和組合物
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
JP2017093448A5 (ja)
RU2015128098A (ru) Конструирование систем, способы и оптимизированные направляющие композиции для манипуляции с последовательностями
EP3012324A3 (en) Modulation of hsp47 expression
JP2018512155A5 (ja)
WO2014108850A3 (en) High throughput transcriptome analysis
RU2013139298A (ru) Способ конструирования специфичных промоторов
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
MX2007004686A (es) Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos.
WO2020198509A3 (en) Modified oligonucleotides with increased stability
JP7440045B2 (ja) 核酸封入aav中空粒子
CA3216819A1 (en) Gene expression regulatory system using crispr system